类固醇诱发的骨质疏松-培训课件.pptVIP

Cyclical Etidronate and Prevention of Corticosteroid-Induced Bone Loss *P0.05 between-group difference. Adachi JD, et al, 1997. Roux C, et al,1998. * * -4 -3 -2 -1 0 1 2 Lumbar spine Femoral neck Trochanter Lumbar spine Femoral neck Trochanter Changes in BMD from baseline (%) at 1 year Etidronate Control 0 2 4 6 Lumbar spine* Femoral neck Trochanter Change in BMD from baseline (%) Men Pre-menopausal women Post-menopausal women Etidronate: Pooled Results from Three Randomized Trials *P0.05 between-group difference. Roux C, et al,1998. Efficacy of Pamidronate in the Prevention of Bone Loss Boutsen Y, et al, 1997. -6 -4 -2 0 2 4 6 6 months 12 months 6 months 12 months Changes in BMD from baseline (%) Pamidronate + calcium Calcium only Efficacy of Alendronate in Increasing BMD *P 0.001 vs. control; **P 0.01 vs. control; ?P 0.001 vs. baseline, ?P 0.01 vs. baseline; Saag KG, et al, 1998. -1.5 -0.5 0.5 1.5 2.5 3.5 Lumbar spine Femoral neck Trochanter Total body Change in BMD from baseline (%) at 48 weeks Control Alendronate 5 mg Alendronate 10 mg *? *? *? *? ? **? *? **? Efficacy of Alendronate: Two Years Follow-Up *P0.001 vs. control; **P0.01 vs. control; ?P0.05 vs. control. Saag KG, et al, 1998. * * ** ** ? ? -4 -3 -2 -1 0 1 2 3 4 Lumbar spine Femoral neck Trochanter Change in BMD from baseline (%) Control Alendronate 10 mg Alendronate 5 mg Alendronate 2.5 mg year 1, 10 mg year 2 Effect of Risedronate on BMD inPatients Initiating Corticosteroid Therapy *P0.05 vs control. Cohen S, et al, 1998. * * * * * * -4.0 -2.0 0.0 2.0 4.0 Lumbar spine Femoral neck Trochanter Change in BMD from baseline (%) at 12 months Control Risedronate 2.5 mg Risedronate 5 mg Effect of Risedronate on BMD in Patients on Long-Term Corticosteroid Therapy *P0.05 vs. control. Devogelaer JP, et al, 1998. * * * * -3.0 -2.0 -1.0 0.0 1.0 2.0 3.0 Lumbar spine Femoral neck Trochanter Change in BMD from baseline (%) at 12 months Control Risedronate 2.5 mg Risedronate 5 mg 0 5 10 15 20 Pooled control pati